SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial data from ...
Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026 SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE ...
(MENAFN- GlobeNewsWire - Nasdaq) Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026 SAN ...
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
We have updated our Privacy Policy. Please review to learn more. By continuing to use our services, you agree to these updates. By Patty Nieberg Published May 6, 2026 ...
Daraxonrasib is an oral, multi-selective RAS inhibitor from Revolution Medicines Data from this trial previously prompted the Food and Drug Administration (FDA) to grant orphan drug designation to ...
AACR was full of biotechs showcasing their preclinical Ras candidates, including Clasp Therapeutics, Verastem Oncology and BlossomHill Therapeutics. (Darren Incorvaia) After dropping headline-grabbing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results